AUTHORS
Pradeep Ramalingam, MD PhD, Ibtida Tabassum Ishmam, MS2, Bianca Elizabeth Bean, B.S.3, Cody William Carter, BS, MS4, Jason Butler, Ph.D.5, Michael Poulos, PhD6
AFFILIATIONS
1 University of Florida, Gainesville, Florida, United States
2 University of Florida, Gainesville, Florida, United States
3 University of Florida, Gainesville, Florida, United States
4 University of Florida, Gainesville, Florida, United States
5 University of Florida, Gainesville, Florida, United States, University of Florida, Gainesville, Florida, United States
6 University of Florida, Gainesville, Florida, United States
ABSTRACT
Chemotherapy and total body irradiation (TBI) are therapeutic modalities utilized for cancer treatments as well as conditioning prior to bone marrow (BM) transplantations (BMTs). While these myelosuppressive therapies help eradicate malignant cells, they have an adverse impact on the BM microenvironment, particularly the BM vascular niche. Given that hematologic recovery after myelosuppressive therapies is contingent upon efficient regeneration of the BM vascular niche, strategies to mitigate damage to the BM vascular niche following myelosuppressive therapies may accelerate hematologic recovery, minimize conditioning-associated cytopenias, and improve treatment outcomes. However, signaling mechanisms within the BM vascular niche that regulate vascular recovery following myelosuppressive injuries remain poorly defined. Moreover, whether these signaling alterations and the associated long-term functional outcomes are conserved in chemotherapy and irradiation are unknown.
Herein, we performed a temporal transcriptional profiling of BM vascular endothelial cells (BMECs) following TBI and 5-Fluorouracil (5FU) to define transcriptional alterations during myelosuppressive recovery. Young (4-month-old) C57BL6 were given a single dose TBI (550 Rad) or administered a single dose of 5FU (150mg/kg i.p.), doses previously shown to result in similar degrees of BM vascular damage. BMECs were isolated on days 1, 3, 7, 14, and 56 (N=4 mice/group/time-point) and RNA-Seq was performed as per standard protocols. Gene expression analyses revealed massive transcriptional alterations at the early (days 1 & 3), intermediate (days 7 & 14), and late (day 56) stages of vascular recovery with significant divergence in signaling pathways related to cell cycle, DNA damage, metabolism, and inflammation in TBI versus 5FU. While TBI caused a persistent upregulation of interferon-response pathways, 5FU caused an earlier induction and sustained upregulation of glycolysis, cell cycle and DNA damage response pathways. Accordingly, immunofluorescence analysis revealed that TBI, but not 5FU, resulted in persistent DNA damage (γH2AX foci) and quiescence (mKi67 expression) in BMECs at day 56. These findings align with the greater incidence of vasculopathy observed in patients receiving TBI as compared to 5FU.
Given that vascular regeneration has been shown to occur earlier following 150 mg/kg 5FU as compared to 550 Rad TBI, we examined the kinetics of canonical angiogenesis-regulating signaling pathways within BMECs. Our analysis revealed that angiogenesis pathways, and their regulatory transcription factor networks, showed an earlier and more robust induction in 5FU as compared to TBI explaining the faster vascular recovery observed in 5FU. Notably, the axon guidance signaling pathway showed the most pronounced induction amongst angiogenesis pathways during days 1 to 14 in both modalities of myelosuppression, indicating a putative role for this signaling pathway in regulating vascular niche regeneration and hematologic recovery. To verify this, we subjected young C57BL6 mice to 550 Rad TBI and treated them with the axon guidance cue Netrin-1 (Ntn1) (4 µg s.c.) or saline on days 1, 3, 5, 7, and 9. Analysis of blood counts over four weeks revealed significantly accelerated recovery of WBCs, neutrophils, RBCs, and platelets in Ntn1-treated mice as compared to saline-treated mice. Notably, we recently showed that Ntn1 can also accelerate hematologic recovery following 5FU administration. To test whether Ntn1 can also promote vascular regeneration, we analyzed BM vascular leakiness following a single dose 5FU (150 mg/kg) administration. Mice were then treated with saline or Ntn1 (4 µg s.c.) on days 1, 3, and 5. Analysis of BM vascular leakiness on day 7 showed that mice treated with Ntn1 had a significantly reduced BM vascular leakiness as compared to mice treated with saline.
In summary, our findings reveal that transcriptional programs and their induction kinetics show significant differences in BMECs during vascular recovery following 5FU and TBI. We show that a single dose of TBI is sufficient to promote senescence within BMECs. Our data suggests that the earlier induction of cell cycle and angiogenesis programs in BMECs following 5FU explains their accelerated vascular recovery as compared to TBI. We identify that the axon guidance cue Ntn1 can accelerate BM vascular niche regeneration and promote hematologic recovery following myelosuppressive therapies.
DISCLOSURES
Pradeep Ramalingam, MD PhD: No relevant conflicts of interest to declare.